Published in Genetics and Environmental Health Week, August 22nd, 2007
Total revenue increased to $14.7 million in the second quarter of 2007 compared to $8.4 million in the second quarter of 2006. Product revenue from Oncotype DX(TM) was $14.6 million in the second quarter of 2007 compared to $7.8 million in the second quarter of 2006. Contract revenue was the balance of total revenue for each of these periods.
"Product revenue in the second quarter was stronger than our expectations, and we made important reimbursement progress," said Randy Scott, Ph.D., Chairman and Chief Executive Officer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.